title: High-dose cutaneous exposure to mite allergen induces IgG-mediated protection against anaphylaxis.
abstract: The relationship among natural allergen exposure, induction of blocking antibody and the occurrence of atopic allergy-particularly in the presence of IgE production-is debatable.
  
  
  
  To clarify the relationship between the dose of cutaneous exposure to dust mite allergen and susceptibility to the IgE-mediated allergic response in relation to IgG production.
  
  
  
  NC/Nga mice were epicutaneously exposed to various doses of Dermatophagoides pteronyssinus allergen to induce atopic dermatitis-like skin lesions. We then evaluated the skin lesions, induction of mite-specific immune responses, and susceptibility to anaphylaxis.
  
  
  
  Dose-dependent exacerbation of atopic dermatitis-like skin lesions and increases in mite-specific IgG and IgE production were observed. However, mice exposed to relatively low doses of mite allergen showed hypersusceptibility to mite allergen-specific anaphylaxis. We also showed that adoptive transfer of total IgG from Dp-sensitized mice rescued mice from the hypersusceptibility seen in those exposed to low doses of mite allergen.
  
  
  
  High-dose cutaneous exposure to dust mites induced effective blocking IgG production, even if accompanied by IgE production. Our data might support the concept that an increase in IgG titre, not a decrease in IgE titre, is a marker of clinical improvement in allergen-specific immunotherapy.
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Hirai
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.|Vaccine Creation Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.|BIKEN Center for Innovative Vaccine Research and Development, The Research Foundation for Microbial Diseases of Osaka University, Osaka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Yoshioka
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.|Vaccine Creation Project, BIKEN Innovative Vaccine Research Alliance Laboratories, Research Institute for Microbial Diseases, Osaka University, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Takahashi
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Handa
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Izumi
authors.affiliation: Laboratory of Innovative Antibody Engineering and Design, Center for Drug Innovation and Screening, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
authors.forename: T
authors.initials: T
authors.lastname: Mori
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: E
authors.initials: E
authors.lastname: Uemura
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: N
authors.initials: N
authors.lastname: Nishijima
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Sagami
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: M
authors.initials: M
authors.lastname: Yamaguchi
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Eto
authors.affiliation: Laboratory of Biopharmaceutical Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Nagano
authors.affiliation: Laboratory of Biopharmaceutical Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.|The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kamada
authors.affiliation: Laboratory of Biopharmaceutical Research, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.|The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Tsunoda
authors.affiliation: Laboratory of Adjuvant Innovation, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.|Laboratory of Vaccine Science, Immunology Frontier Research Center, World Premier International Research Center, Osaka University, Osaka, Japan.
authors.forename: K J
authors.initials: KJ
authors.lastname: Ishii
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Higashisaka
authors.affiliation: Laboratory of Toxicology and Safety Science, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan.|Laboratory of Innovative Antibody Engineering and Design, Center for Drug Innovation and Screening, National Institutes of Biomedical Innovation, Health and Nutrition, Osaka, Japan.|The Center for Advanced Medical Engineering and Informatics, Osaka University, Osaka, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Tsutsumi
mesh_terms: D000485:Allergens / Q000008:administration & dosage* / Q000276:immunology*; D000707:Anaphylaxis / Q000276:immunology / Q000378:metabolism / Q000517:prevention & control*; D000818:Animals; D019138:Antibodies, Blocking / Q000276:immunology*; D000918:Antibody Specificity / Q000276:immunology; D039741:Antigens, Dermatophagoides / Q000008:administration & dosage* / Q000276:immunology*; D016207:Cytokines / Q000378:metabolism; D004195:Disease Models, Animal; D005260:Female; D007114:Immunization; D007073:Immunoglobulin E / Q000097:blood / Q000276:immunology; D007074:Immunoglobulin G / Q000097:blood / Q000276:immunology*; D051379:Mice
chemical_list: D000485:Allergens; D019138:Antibodies, Blocking; D039741:Antigens, Dermatophagoides; D016207:Cytokines; D007074:Immunoglobulin G; D007073:Immunoglobulin E
keywords: IgE; anaphylaxis; blocking antibody; dust mite; skin